Hesperetin as an adjuvant augments protective anti‐tumour immunity responses in B16F10 melanoma by stimulating cytotoxic CD8+ T cells. (4th February 2020)

• Record Type: Journal Article
• Authors: Jiang, Shasha; Wang, Shuang; Zhang, Lina; Tian, Le; Li, Ling; Liu, Zeyuan; Dong, Qiwen; Lv, Xue; Mu, Haiyu; Zhang, Qianwen; Wang, Bin
• Is Part Of: Scandinavian journal of immunology. Volume 91:Number 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-02-04
• Subjects: hesperetin -- melanoma -- T cells -- tumour immunity -- vaccination; Immunology -- Periodicals; 571.96
• DOI: 10.1111/sji.12867
• Languages: English
• ISSNs: 0300-9475

Abstract

Abstract: Hesperetin (HES) is a dihydroflavone with the molecular formula of C16H14O6. It has been reported that Hesperetin has antioxidant and anticancer effects. Recent studies showed that it can also regulate immune responses. To assess its potential function as a vaccine adjuvant, we formulated HES with inactivated B16F10 melanoma cells and determined whether it would enhance the activation of antigen‐presenting cells by experiments in vivo and in vitro. We found that HES activated the PI3K‐Akt signalling pathway in antigen‐presenting cells (APCs), enhanced cytotoxic T lymphocyte (CTL) responses and deactivated tolerogenic T cells. We also observed that inactivated B16F10 cells in combination with HES vaccine inhibited the growth of mice tumours, resulting in improved overall survival compared to the effects of inactivated B16F10 cell vaccine. To verify that CD8 + T cells play a key role in inhibiting the development of melanoma, we transferred the sorted CD8 + T cells from immunized mice to B16F10 challenged models and found that the survival rate of tumour‐bearing mice was significantly prolonged. Taken together, these results suggest that hesperetin can be used as a potential adjuvant to improve tumour immune responses and antigen immunogenicity.